Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
| Autor: | Klaus Baumann, S. Loibl, Antje Belau, H. Eidtmann, Keyur Mehta, Manfred Dietel, S. T. Grasshoff, C. Thommsen, Hans Tesch, Hans-Juergen Holzhausen, G. von Minckwitz, Bruno Valentin Sinn, G Hoffmann, Carsten Denkert, Ralf Kronenwett, Silvia Darb-Esfahani |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Survival medicine.medical_treatment Gene Expression Breast Neoplasms Docetaxel Disease-Free Survival Breast cancer Internal medicine Gene expression medicine Biomarkers Tumor Humans RNA Messenger skin and connective tissue diseases neoplasms Cyclophosphamide Neoadjuvant therapy MUC1 Predictive marker business.industry Mucin-1 Hematology Immunotherapy Middle Aged medicine.disease digestive system diseases Neoadjuvant Therapy Treatment Outcome Receptors Estrogen Doxorubicin Immunohistochemistry Female Taxoids business Receptors Progesterone medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 24(9) |
| ISSN: | 1569-8041 |
| Popis: | Background: Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer. Patients and methods: Pre-treatment core biopsies of patients from the GeparTrio neoadjuvant trial (NCT 00544765) were evaluated for MUC1 by immunohistochemistry (IHC; N = 691) and quantitative RT-PCR (qRT-PCR; N = 286) from formalin-fixed paraffin-embedded (FFPE) samples. Results: MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptor-positive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015). Conclusions: MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|